Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596

Migma AI turns this inspiration into an email with your brand’s colors, fonts, and voice.

Create this for my brand

Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596 email from Novo Nordisk screenshot

Make this email yours.

Design observations

Novo Nordisk announces an exclusive license agreement with Hengrui Pharma for HRS-1596, an oral GLP-1/GIP dual receptor agonist.

Visual structure

Logo at top left, followed by bullet points highlighting deal details, then a standard corporate press release layout with multiple paragraphs, contact information tables, and legal footer.

Email details

Captured: September 29, 2026
Email type: Announcement
Industry: Vitamins & Nutrition
AI design score: 4/10
Language: English
Tone: Professional
Style: Text-heavy
Journey stage: Awareness
CTA count: 1
Animated GIF: No
Dark mode: No

Color palette

How does Migma learn my brand?

Import your website in Migma, then review your logo, colors, fonts, and brand voice. AI uses those settings and your brief to create an editable email. See how brand setup works.

Was this example made with Migma AI?

This is an archived brand email, shown for inspiration. The archive does not establish how it was made. Remixing starts a new email for your own brand.

What can I download or export?

Download preview saves an image of this example. Export HTML downloads its original source on a paid plan, subject to daily limits. You can also edit and export the new email you create in Migma. View plans.

Archived for design inspiration. Original email and brand assets belong to their respective owners. Design observations describe the creative; they are not campaign results.